SIRPA and melanoma: Concordantly, Liu et al. recently demonstrated that treatment with a bispecific anti-PD-L1/SIRPα mAb induced effective, combined adaptive and innate antitumoral immune responses against PD-L1- and CD47-expressing solid tumors, including colorectal cancer and melanoma (73).